25th July 2019
- 0 comments
Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout[1] investments, announces the acquisition of Infarco’s majority stake in 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in the process development and GMP manufacturing of biologics.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage